Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Department of General Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Am J Med Genet C Semin Med Genet. 2023 Jun;193(2):147-159. doi: 10.1002/ajmg.c.32038. Epub 2023 Mar 9.
Pathogenic variants in COL1A1 and COL1A2 are involved in osteogenesis imperfecta (OI) and, rarely, Ehlers-Danlos syndrome (EDS) subtypes and OI-EDS overlap syndromes (OIEDS1 and OIEDS2, respectively). Here we describe a cohort of 34 individuals with likely pathogenic and pathogenic variants in COL1A1 and COL1A2, 15 of whom have potential OIEDS1 (n = 5) or OIEDS2 (n = 10). A predominant OI phenotype and COL1A1 frameshift variants are present in 4/5 cases with potential OIEDS1. On the other hand, 9/10 potential OIEDS2 cases have a predominant EDS phenotype, including four with an initial diagnosis of hypermobile EDS (hEDS). An additional case with a predominant EDS phenotype had a COL1A1 arginine-to-cysteine variant that was originally misclassified as a variant of uncertain significance despite this type of variant being associated with classical EDS with vascular fragility. Vascular/arterial fragility was observed in 4/15 individuals (including one individual with an original diagnosis of hEDS), which underscores the unique clinical surveillance and management needs in these patients. In comparison to previously described OIEDS1/2, we observed differentiating features that should be considered to refine currently proposed criteria for genetic testing in OIEDS, which will be beneficial for diagnosis and management. Additionally, these results highlight the importance of gene-specific knowledge for informed variant classification and point to a potential genetic resolution (COL1A2) for some cases of clinically diagnosed hEDS.
COL1A1 和 COL1A2 中的致病变体与成骨不全症(OI)有关,极少数情况下与埃勒斯-当洛斯综合征(EDS)亚型和 OI-EDS 重叠综合征(OIEDS1 和 OIEDS2)有关。在这里,我们描述了一组 34 名 COL1A1 和 COL1A2 中可能存在致病和致病变体的个体,其中 15 名具有潜在的 OIEDS1(n=5)或 OIEDS2(n=10)。在具有潜在 OIEDS1 的 4/5 例中存在主要 OI 表型和 COL1A1 移码变体。另一方面,9/10 例潜在的 OIEDS2 病例具有主要 EDS 表型,其中包括 4 例最初诊断为高活动度 EDS(hEDS)。另一个具有主要 EDS 表型的病例具有 COL1A1 精氨酸到半胱氨酸变体,尽管这种类型的变体与伴有血管脆弱性的经典 EDS 相关,但最初被错误分类为意义不明的变体。在 15 名个体中的 4/15 名个体中观察到血管/动脉脆弱性(包括一名最初诊断为 hEDS 的个体),这突显了这些患者独特的临床监测和管理需求。与之前描述的 OIEDS1/2 相比,我们观察到了不同的特征,这应该被考虑用来细化目前在 OIEDS 中进行基因检测的标准,这将有助于诊断和管理。此外,这些结果强调了针对特定基因的知识对于知情变体分类的重要性,并指出了一些临床诊断为 hEDS 的病例可能具有潜在的基因解决方案(COL1A2)。